Does the HPMCAS grade (LF, MF, HF) change how much a cationic, lipophilic weak base slows release from an ASD, and does this follow insoluble drug–polymer complex formation and drug ionization?
Yes. At pH 6.8 release ranked LF > MF > HF for both drugs: loratadine drug release about 0.25 vs 0.01 mg·min⁻¹·cm⁻² for LF vs HF, and no measurable release from the cinnarizine–HF ASD. In pH 6.0 buffer HF lost more polymer to an insoluble complex with cinnarizine than LF (99 vs 70% at 1:1), and less ionized drug (loratadine, higher pH) both complexed less and narrowed the grade gap. ····
Release of the two cationic weak bases from 25% DL HPMCAS ASDs varied with polymer grade and with drug ionization: the faster-dissolving LF grade released drug and polymer fastest and HF slowest at pH 6.8, and for loratadine the LF/HF gap fell from over 10-fold at pH 6.8 to under 2-fold at pH 7.5. ····· In pH 6.0 buffer the drug removed polymer from solution as an insoluble complex, more for HF than for LF at any drug/COOH ratio and less when the drug was less ionized (loratadine, higher pH), and the authors conclude that this electrostatic complexation "compromised" release. ···· They explain LF's advantage by its lower hydrophobicity, which lowers the ionization it needs to dissolve ("A similar explanation can be applied"), and by twice the COOH per gram of HF, which leaves "spare" carboxylates to hydrate ("fairly straightforward to rationalize"). ··· The scope is two lipophilic weak bases at one drug loading (25%) in 50 mM phosphate at pH 6.8 and 7.5 (cinnarizine at pH 6.8 only), with most MF data taken from the group's earlier work; complex formation and surface pH were not measured inside the dissolving ASD, and the grade mechanism was proposed, not measured. ····
01Why this study
Drug release from an ASD is enhanced when it is coupled to the more soluble polymer, giving congruent release.
Indulkar 2019, ref 15; refs 26–36
HPMCAS dissolves only once a critical fraction of its COOH groups is ionized and the chains can hydrate.
Hiew 2022, ref 45; Tsiartas 1997, ref 46
Weak bases that were cationic at the dissolution pH released poorly from MF ASDs, attributed to hydrophobic ion pairs that reduce polymer hydration.
Bapat 2024, ref 3
LF has the most succinoyl (ionizable) groups, HF the most acetyl (hydrophobic) groups.
Ueda 2020, ref 13; refs 40, 41, 49, 50, 55–58
More detail
What was already known. The introduction builds on these points:
- ASDs need a polymer, and the polymer drives release. The amorphous form gives a higher apparent solubility but is unstable, so it is formulated with a polymer that inhibits crystallization and improves release. Release improves because the polymer is more soluble than the drug; when drug release is coupled to the polymer, the two leave together (congruent release). HPMCAS is a common ASD polymer, especially for spray drying. (refs 1–41; Indulkar 2019, ref 15; Saboo 2019, ref 27)
- Critical ionization fraction model. For an acidic polymer that is insoluble at low pH, dissolution starts only when a critical fraction of its ionizable groups is ionized, and the rate then rises with further ionization. Ionization to carboxylate brings hydration, plasticization and dilution of the chains. Anything that hinders hydration, for example a hydrophobic drug interacting strongly with the carboxylate in the ASD, "can impact" polymer solubility and dissolution rate. (Hiew 2022, ref 45; Tsiartas 1997, ref 46) ·
- Grade studies have focused elsewhere. HPMCAS-LF, -MF and -HF have been compared mainly for crystallization inhibition and for the drug-rich nanodroplets formed on dissolution; few studies looked at release kinetics, and the effect of molecularly dispersed drug on polymer release is "largely unexplored". (refs 4, 7, 13, 14, 23, 38, 39, 41, 47–54)
- The group's own HPMCAS-MF study. With weak acid, neutral and weak base drugs in MF, weak bases that were cationic at the dissolution pH released poorly; this was attributed to hydrophobic ion pairs formed by electrostatic interaction between drug and polymer, reducing polymer hydration. Under mutual ionization, release fell and insoluble drug–polymer complexes increased. (Bapat 2024, ref 3)
- Grades differ in their substituents. The grades differ in amounts and ratios of succinoyl (ionizable, hydrophilic) and acetyl (hydrophobic) groups: LF has the most succinoyl, HF the most acetyl. How ionic interactions with lipophilic cationic drugs play out across grades has been "little explored". (Ueda 2020, ref 13; refs 40, 41, 49, 50, 55–58) ·
What the paper set out to do. Test the hypothesis that, at equal drug loading, a lipophilic cation impairs release from HF ASDs more than from MF ASDs, with LF ASDs performing best. Two weak bases of different ionization were used, release was measured at two pH values to vary drug ionization, the acid content of the grades was titrated, and complex formation between drug and polymer was measured in solution. ·
02How they approached it
Two lipophilic weak bases that differ in how ionized they are near pH 6–7, three HPMCAS grades that differ in acid content, one drug loading (25%), release at two pH values, and a solution test of how much polymer the drug pulls out as an insoluble complex. ······
What was done
25:75 drug:polymer ASDs by rotary evaporation→100 mg compacts in Wood's apparatus, 37 °C, pH 6.8 and 7.5 (and 1.6)→drug and polymer normalized release rates.····
Neat polymer compacts, same test→intrinsic dissolution rate.·
MF release and IDR from Bapat 2023.···
Potentiometric titration of LF and HF→COOH content and pKa.···
Slurry of each grade in water→surface pH.···
Drug and polymer from THF into pH 6.0 buffer, drug/COOH 0.25:1 to 3:1→% polymer lost as insoluble complex; LOR at 1:1 from pH 5.8 to 7.5; CNZ also at pH 5.8.····
Drug and polymer ionization at each pH from pKa.·
Release rate against complexation and ionization across grades and drugs.··
More detail
What was done
- ASDs. LOR and CNZ were each dispersed at 25% DL in HPMCAS-LF, -MF and -HF by rotary evaporation from methanol:dichloromethane 1:2 v/v, vacuum-dried overnight, cryomilled and sieved to 106–250 µm; PXRD and PLM showed them amorphous. ·
- Release. 100 mg of ASD or neat polymer was compressed at 1500 psi for 1 min into an 8 mm die so that one face (0.5 cm²) faced 100 mL of 50 mM phosphate buffer at 37 °C, rotating at 100 rpm. Samples were taken over 60 min and the medium replenished; drug was assayed by HPLC-UV and polymer by HPLC with an evaporative light scattering detector. The pH stayed within ± 0.1 of target. Release was run at pH 6.8 and 7.5 (LOR ASDs, neat polymers), pH 6.8 only (CNZ ASDs) and pH 1.6 (all six ASDs, drug only); n = 3. MF results at pH 6.8 and 7.5 were taken from the group's earlier media study. ·····
- Crystallization check. After release the solution and the compact surface were inspected by polarized light microscopy, at 1 h and up to about 12 h. ·
- Titration. Dried LF and HF were dissolved with excess NaOH and back-titrated with 0.1 N HCl. The HCl volume between the first end point (excess NaOH neutralized) and the second (all polymer precipitated) gives the COOH content; the half-neutralization point gives the pKa; n = 2. MF values came from Hiew 2022. ··
- Surface pH. Excess polymer was stirred in water overnight; the final slurry pH was taken as the lowest possible surface pH during dissolution. ·
- Complexation. Drug, polymer, or drug plus polymer were dissolved in THF and a small aliquot added to stirred phosphate buffer so that the polymer was at 0.5 mg/mL (well below its 4–8 mg/mL solubility in pH 6.0 buffer) and the drug above its amorphous solubility. Drug alone precipitated, polymer alone stayed dissolved, and drug plus polymer turned turbid with polymer in the pellet; after centrifugation the polymer left in the supernatant was measured by the phenol–sulfuric acid method. CNZ was tested at drug/COOH ratios of 0.25:1 to 3:1 at pH 6.0 (LF, HF) and at pH 5.8 (LF, MF); LOR at 1:1 from pH 5.8 to 7.5; n = 3. ···
- Ionization. The ionized fraction of each drug at each pH, and of HPMCAS at pH 5.8, was calculated from pKa (relation not printed). ·
Key equations
The slope k of concentration versus time, times the medium volume V (100 mL), divided by the exposed area S (0.5 cm²) and by the weight fraction x of the component in the compact. Dividing by x puts drug and polymer on the same scale, so equal values mean congruent release.·
The share of the added polymer that no longer stays in solution once the drug is present; the paper reads it as polymer bound in an insoluble drug–polymer complex.·
Terms used on this page
- Normalized release rate: release per minute and per cm² of compact surface, divided by the component's weight fraction (Eq. 1). For a neat polymer it is the intrinsic dissolution rate (IDR).
- Congruent release: drug and polymer leave the compact at the same normalized rate, so the drug travels with the dissolving polymer.
- Critical ionization extent: the fraction of an enteric polymer's acid groups that must be ionized before it dissolves.
- Drug/COOH molar ratio: moles of drug per mole of polymer carboxylic acid groups; at 1:1 there is one drug molecule per acid group.
- % complexation: polymer lost from solution into a pellet with the drug (Eq. 2).
- Surface pH: the pH at the dissolving surface; here estimated from a polymer slurry in water, or cited for the ASD surface.
03Main findings
Neat LF dissolves about 3 times faster than HF
IDR at pH 6.8: LF about 1.50, MF 0.90, HF 0.45 mg·min⁻¹·cm⁻²; all faster at pH 7.5 (about 1.73, 1.09, 0.63). ·
More detail
Compacts of the neat grades dissolved in the order LF > MF > HF at both pH values, and each grade dissolved faster at pH 7.5 than at pH 6.8. LF was about 3-fold faster than HF at both pH (read from Fig. 2: about 1.50 vs 0.45 mg·min⁻¹·cm⁻² at pH 6.8, about 1.73 vs 0.63 at pH 7.5). The MF values were taken from the group's earlier study. ··
Loratadine ASDs: grade matters greatly at pH 6.8, much less at pH 7.5
Drug release at pH 6.8: LF about 0.25, MF 0.10, HF 0.01 mg·min⁻¹·cm⁻² (LF/HF over 10-fold); at pH 7.5: about 0.73, 0.62, 0.44 (under 2-fold). Polymer left at about the same rate as the drug. ··
More detail
For 25:75 LOR:HPMCAS ASDs, drug and polymer normalized rates were close in every system (read from Fig. 3: drug/polymer about 0.25/0.27 for LF, 0.10/0.12 for MF and 0.01/0.02 for HF at pH 6.8; 0.73/0.76, 0.62/0.68 and 0.44/0.48 at pH 7.5). The order LF > MF > HF held at both pH. Moving from pH 6.8 to 7.5 raised the HF ASD rate by more than an order of magnitude, the MF ASD by about 5-fold and the LF ASD by about 3-fold, so the grade differences shrank. After 1 h the LOR concentration reached 17.6, 7.0 and 2.4 µg/mL (LF, MF, HF) at pH 6.8 and 59.1, 39.9 and 29.2 µg/mL at pH 7.5. In the slowest system (HF, pH 6.8) the plotted drug rate is about half the polymer rate. ····
Cinnarizine ASDs: LF releases about 9 times faster than MF, and HF does not release measurably
Drug release at pH 6.8 about 0.13 (LF) vs 0.014 (MF) mg·min⁻¹·cm⁻²; the HF rate was "too slow to be determined", with 0.0 µg/mL in solution after 1 h. ··
More detail
For 25:75 CNZ:HPMCAS ASDs at pH 6.8, drug and polymer rates were about 0.130 and 0.140 mg·min⁻¹·cm⁻² for LF and about 0.014 and 0.025 for MF (read from Fig. 4; MF from the earlier study). The authors give a factor of about 9 between LF and MF. The HF ASD released too slowly to determine a rate. After 1 h the solution held 5.3 (LF), 2.7 (MF) and 0.0 µg/mL (HF) CNZ. At the same grade, CNZ released more slowly than LOR (LF drug rate about 0.13 vs 0.25). ····
LF carries twice the acid groups of HF, at nearly the same pKa
COOH content 1.52 (LF), 1.19 (MF, cited) and 0.76 mmol/g (HF); pKa 4.91, 4.97 and 5.06. ··
More detail
Titration of dissolved LF showed a clear buffering plateau near pH 4.9 followed by a steep drop between about 1300 and 1600 µL of 0.1 N HCl; HF fell more gradually without a flat plateau (Fig. 5). From the end points, LF has 1.52 ± 0.03 and HF 0.76 ± 0.02 mmol/g COOH (n = 2), twice as many acid groups per gram for LF; the MF value of 1.19 ± 0.01 mmol/g was taken from Hiew 2022. The pKa values, taken as half-neutralization points, differ little: 4.91 ± 0.01 (LF), 4.97 ± 0.02 (MF) and 5.06 ± 0.02 (HF). ····
HF loses more polymer to an insoluble complex with cinnarizine than LF
At pH 6.0 and the same CNZ/COOH ratio, HF lost 70% of its polymer at 0.25:1 and 99% at 1:1; LF lost 30% and 70%; MF lay in between (cited). ···
More detail
Adding CNZ and polymer together to pH 6.0 buffer gave a turbid suspension whose pellet contained polymer, whereas the same polymer alone stayed dissolved. · The polymer fraction lost rose with the CNZ/COOH ratio for every grade. For HF it was 70 ± 2, 86 ± 6, 98 ± 4 and 99 ± 3% at 0.25, 0.5, 0.75 and 1:1, and 98% at 1.5 and 2:1. For LF it was 30 ± 5, 45 ± 3, 65 ± 4, 70 ± 6, 85 ± 2 and 95 ± 3% over the same ratios up to 2:1. The cited MF values (about 41, 67, 82 and 90% up to 1:1) fell between the two, and all three grades reached about 100% at 3:1. · The authors read the lower LF values as LF staying more soluble in the presence of the drug at a given stoichiometry ("suggesting"). Table 4 also converts each ratio to an ASD drug loading; for example 1:1 corresponds to 36% DL for LF but 22% for HF. The printed 88% DL for LF at 2:1 is out of line with the other rows (about 53% expected). ·
Complex formation follows drug ionization
At 1:1 and pH 6.0, LOR (about 14% ionized) removed 50% of LF, against 70% for fully ionized CNZ. LOR complexation fell steeply with pH, to about 2% (LF) and 40% (HF) at pH 6.8. Lowering pH to 5.8 raised CNZ complexation (LF at 1:1 about 81 vs 70%). ·····
More detail
At a 1:1 LOR/COOH ratio and pH 6.0, HF lost 95 ± 3% and LF 50 ± 6% of its polymer (CNZ with LF at 1:1: 70 ± 6%). Across pH, complexation fell as pH rose for all three grades: HF from about 95% at pH 6.0 to 67% at 6.5, 40% at 6.8 and 15% at 7.5; LF from about 70% at 5.8 and 50% at 6.0 to 13% at 6.5 and about 2% and 0% at 6.8 and 7.5; MF (cited) from about 85% to 2%. Over the same range the calculated LOR ionization fell from about 20% at pH 5.8 and 14% at 6.0 to about 2.5% at 6.8 and 0.5% at 7.5 (Fig. S1). ···· For CNZ, which stays fully ionized, lowering the pH from 6.0 to 5.8 raised complexation at every ratio: LF from 30–70% to about 40–81%, MF from about 41–90% to about 50–100%. The authors explain this by HPMCAS being less ionized at pH 5.8 (89% with pKa 4.9) and so less soluble, while the ratio of drug cations to polymer anions rises slightly ("This is because"). ···· The paper's ">99.9%" ionization for CNZ at pH 6.0 recomputes to about 99.6% from pKa 8.4.
04Further observations
- Little release in acid. At pH 1.6, 2.1–5.5% of the drug was released in 1 h from all six ASDs. ·
- No crystallization. None during the 1 h release; none for 12 h from MF and HF ASDs; small crystals only after about 10 h for LOR–LF. ·
- Above amorphous solubility. LOR–LF reached 17.6 µg/mL at pH 6.8 and 59.1 µg/mL at pH 7.5 after 1 h, against amorphous solubilities of 9.0 and 7.6 µg/mL. ··
- Surface pH. Slurry pH rose from LF (4.52) to MF (4.61) to HF (4.73). ···
More detail
- Release in acid (pH 1.6, about 0.02 M HCl). Drug normalized release rates were 0.06–0.09 mg·min⁻¹·cm⁻² and 2.1–5.5% of the drug was released after 1 h, without crystallization. The text says release was below 5% for every ASD, but Table S3 gives 5.5 ± 0.07% for CNZ–LF; and the pH 1.6 drug rates are higher than the pH 6.8 drug rates of the LOR–HF and CNZ–MF ASDs. ···
- Crystallization did not cause the slow release. No crystals were seen by polarized light in solution or on the compact surface during the 1 h tests; none appeared for up to 12 h after release from MF and HF ASDs of either drug, and small crystals appeared in solution after about 10 h only for the LOR–LF ASD. The authors take this as assurance that slow release was not caused by crystallization. ·
- Solution concentrations after 1 h. LOR reached 17.6 (LF), 7.0 (MF) and 2.4 µg/mL (HF) at pH 6.8 and 59.1, 39.9 and 29.2 µg/mL at pH 7.5; CNZ reached 5.3, 2.7 and 0.0 µg/mL at pH 6.8. The cited crystalline and amorphous solubilities are 1.8 and 9.0 µg/mL for LOR at pH 6.8, 1.4 and 7.6 µg/mL at pH 7.5, and 2.1 and 12.0 µg/mL for CNZ at pH 6.8. Several LOR values exceed the amorphous solubility, which the paper does not discuss; whether the samples include drug-rich colloids is not stated. ··· For the CNZ ASDs the 1-h concentrations do not match the plotted rates through Eq. 1.
- Slurry (surface) pH. LF 4.52 ± 0.04, MF 4.61 ± 0.02, HF 4.73 ± 0.03: LF is the most acidic, which the authors relate to the grades' different solubilities. The MF value has no stated source. ····
05How the authors connect the findings
More detail
- The critical ionization model says an enteric polymer starts to dissolve only after a critical fraction of its acid groups is ionized; ionization brings hydration, plasticization and dilution of the chains. A drug that binds the carboxylates and blocks their hydration should therefore slow dissolution ("can impact"). ·
- Following the group's earlier work, the dissolving ASD surface is taken to be near pH 6.0 when the bulk is pH 6.8 in 50 mM phosphate, which is why complexation was tested at pH 6.0. There, a cationic drug forms hydrophobic ion pairs with the carboxylates, and drug and polymer drop out of solution together. ···
- Polymer solubility at the interface sets how fast polymer diffuses through the boundary layer into the bulk; since the drug leaves with the polymer (similar normalized rates), anything that lowers interfacial polymer solubility lowers drug release too. ·
LF grade, or a less ionized drug. By analogy with Heller's maleic anhydride copolymers, where a larger hydrophobic group raised the ionization needed to dissolve from 3% to 91% at unchanged pKa, LF, with relatively more succinoyl than acetyl groups, needs less ionization to dissolve ("A similar explanation can be applied"). At 25% DL, LF also has twice the carboxylates per gram of HF, leaving "spare" ones not paired with the drug to keep hydrating ("fairly straightforward to rationalize"). A less ionized drug such as LOR at pH 6.0 binds fewer carboxylates, so LF stays more soluble and the LOR–LF ASD releases faster than the CNZ–LF ASD, "most likely" because of lower complexation rather than lipophilicity (log P 5.2 vs 5.8). ····
HF grade with a fully ionized drug. HF has the fewest acid groups and is the most hydrophobic; a fully ionized drug such as CNZ binds nearly all of them (99% complexation at 1:1 in solution), so the polymer cannot dissolve and release stalls. ····
What sets the switch point. The ratio of drug cations to available carboxylates. It rises with drug loading and falls with COOH content (LF has twice that of HF), and the fraction of drug that is cationic falls as pH rises above the drug's pKa, which is why LOR complexation dropped steeply from pH 6.0 to 6.8 and why raising pH narrowed the grade gap. Lowering the pH to 5.8 raises complexation of the fully ionized CNZ because the polymer itself becomes less ionized and less soluble. ···
Conclusion drawn. Release "was compromised by drug/polymer electrostatic interactions leading to the formation of an insoluble complex", more so for HF than LF, and depends on drug ionization and hence the medium pH. The observations "highlight the convoluted release behavior" of acidic polymer–basic drug ASDs and give a baseline for more physiological media. ·
06What it means for formulation
- With lipophilic weak bases ionized at the dissolution pH, LF gave better release than MF or HF.
- Stability gains from drug–polymer salt formation should ideally be balanced against the reduced release seen under mutual ionization.
- For a cationic lipophilic drug in HPMCAS, LF is the safer grade, and a quick complexation test at the expected surface pH can flag risky drug–grade pairs before release testing.
More detail
- At a pH where both drug and polymer are ionized, LF showed improved release with the model weak-base lipophilic drugs relative to MF and HF, and release from LF ASDs was less impacted by the cationic drug than from HF ASDs.
- The popularity of HPMCAS and the interest in drug–polymer salts for physical stability "warrant" study of ionic interactions on release; "Ideally" the stability gain is balanced against reduced release under mutual ionization.
- Components molecularly mixed with an enteric polymer that impede hydration of a critical number of ionizable groups are "likely to be detrimental" for release.
- At a fixed drug loading the drug/COOH ratio depends on the grade. By the paper's own Table 4 conversion, 25% DL of CNZ lies between 0.5:1 and 0.75:1 for LF but between 1:1 and 1.5:1 for HF, so in an HF ASD the cationic drug can outnumber the carboxylates, which fits the near-zero release of the CNZ–HF ASD.
- The pH 6.0 complexation test is cheap (THF stock into buffer, colorimetric polymer assay) and ranked the grades in the same order as release; it could serve as a screen for drug–grade pairs. It was validated here on two drugs only.
- For weak bases with a low pKa, such as LOR, the penalty shrinks at higher intestinal pH; a high-pKa base such as CNZ stays ionized across that range and was not tested at pH 7.5.
- Choosing a more hydrophobic grade for other reasons, such as crystallization inhibition, may cost release when the drug is cationic at the dissolution pH.
07Open questions
- How do solubilizing components of biorelevant intestinal fluids change drug–polymer complex formation and release?
- Complex formation and surface pH inside the dissolving ASD were not measured.
- Only one drug loading (25%) was tested.
More detail
- What is the effect of solubilizing components, such as those of simulated intestinal fluids, on drug–polymer complex formation and release?
- How can the physical-stability benefit of drug–polymer salt formation be balanced against reduced release under mutual ionization?
- Whether the complex forms at the dissolving ASD surface, and what the surface pH of these ASDs actually is, was not measured; the link from solution complexation to release is a correlation.
- The proposed grade mechanism (critical ionization extent, spare carboxylates) was not tested; substituent contents of the lots were not reported.
- Only 25% DL was tested, so the drug loading at which each grade fails is unknown.
- MF data come from earlier batches and studies.
- CNZ was not tested at pH 7.5, and LOR was not tested at intermediate release pH values.
- Why several 1-h LOR concentrations exceed the amorphous solubility, and why CNZ concentrations and rates disagree, is not addressed. ·
08How solid
AI assessment, not a statement made in the paperThe release and complexation rankings are direct, replicated and consistent across two drugs and two pH values. The causal link and the grade mechanism are inferred, and the MF data are cross-study. ······
More detail
- Release ranking LF > MF > HF for both drugs at pH 6.8, with drug and polymer measured separately, n = 3. ·
- The neat polymers rank the same way, so the order is not created by the drug alone.
- Complexation ranks HF > MF > LF at every CNZ ratio and HF > MF > LF across pH for LOR, n = 3, with clear controls (drug alone and polymer alone). ···
- LOR complexation drops steeply with pH as its calculated ionization drops, for all three grades. ·
- Crystallization was checked and excluded during the release tests.
- MF release, IDR and pH 6.0 complexation data come from earlier studies and batches.
- Complexation was measured from THF stocks in buffer, not in the dissolving ASD; the surface pH of 6.0 is cited; the release–complexation link rests on two drugs.
- The grade mechanism (critical ionization extent, spare carboxylates) was not measured.
- In the slowest systems the drug rate is about half the polymer rate, so "congruent" holds only for the faster ones.
- Several printed values are inconsistent: 88% DL in Table 4, 5.5% vs "less than 5%" at pH 1.6, CNZ ionization ">99.9%". ··
- For CNZ, 1-h concentrations and plotted rates disagree, and several LOR concentrations exceed the amorphous solubility without comment. ·
- Only 25% DL; CNZ only at pH 6.8; buffers for intermediate complexation pH values not described. ··
09Figure guide
Every figure and table of the paper, what it is there for, and what to check on the original. Key figures are shown with the story.
| Figure | What it does in the paper | Supports | Check (AI note) |
|---|---|---|---|
| Graphical abstract (p.397) | Summarizes the proposed mechanism: equal numbers of occupied carboxylates, fewer free ones from LF to HF. | header | A schematic, not data. |
| Fig. 1 (p.398)key figure | Defines the drugs and the polymer.·· | 0.2 | |
| Table 1 (p.399) | Complexation conditions: ratios, COOH contents, polymer and drug concentrations. | 0.2 | Lists only ratios up to 1:1 and few HF drug concentrations. |
| Fig. 2 (p.400)key figure | Neat polymer IDR, LF > MF > HF at both pH. | F1, K6 | MF bars cited from ref 8. |
| Fig. 3 (p.400)key figure | The main release result for LOR: large grade effect at pH 6.8, small at 7.5. | F2, K1, K2 | Drug about half the polymer rate for HF at pH 6.8. |
| Fig. 4 (p.401)key figure | CNZ release: LF about 9-fold MF; HF not measurable. | F3, K1 | MF bars cited from ref 8; drug about half the polymer rate.· |
| Table 2 (p.401) | 1-h concentrations and cited solubilities. | 0.4 | CNZ values do not match the rates; several LOR values exceed amorphous solubility.· |
| Fig. 5 (p.402)key figure | Titration curves behind the COOH and pKa values. | F4 | |
| Table 3 (p.402)key figure | COOH content and pKa of the grades.·· | F4, K6 | MF values cited from ref 45. |
| Table 4 (p.402) | Complexation versus drug/COOH ratio, with equivalent ASD drug loading. | F5, K3 | 88% DL for LF at 2:1 is out of line (about 53%). |
| Fig. 6 (p.402)key figure | CNZ complexation: HF > MF > LF at every ratio.· | F5, K3 | MF series cited from ref 3. |
| Fig. 7 (p.403)key figure | LOR complexation falls steeply with pH for all grades. | F6, K4, K5 | Buffers for pH 6.0–6.5 not described. |
| Fig. 8 (p.403)key figure | Lower pH (5.8) raises CNZ complexation. | F6 | Source of the MF pH 5.8 data not stated. |
| Table 5 (p.403) | Slurry pH of the grades.·· | 0.4 | Source of the MF value not stated. |
More detail
| Figure | What it does in the paper | Supports | Check (AI note) |
|---|---|---|---|
| Fig. S1 (SI p.2)key figure | LOR complexation replotted against calculated LOR ionization.· | F6, K4 | |
| Table S1 (SI p.2) | Phosphate buffer recipes for pH 6.8, 7.5 and 5.8. | No recipe for pH 6.0. | |
| Table S3 (SI p.3) | Drug release at pH 1.6: 2.1–5.5% in 1 h. | 0.4 | 5.5% contradicts the text's "less than 5%". |